| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Becky C Carlyle, Angus C Nairn, Min Wang, Yang Yang, Lu E Jin, Arthur A Simen, Brian P Ramos, Kelly A Bordner, George E Craft, Peter Davies, Mihovil Pletikos, Nenad Šestan, Amy F T Arnsten, Constantinos D Paspala. cAMP-PKA phosphorylation of tau confers risk for degeneration in aging association cortex. Proceedings of the National Academy of Sciences of the United States of America. vol 111. issue 13. 2014-06-02. PMID:24707050. |
the pattern of neurodegeneration in alzheimer's disease (ad) is very distinctive: neurofibrillary tangles (nfts) composed of hyperphosphorylated tau selectively affect pyramidal neurons of the aging association cortex that interconnect extensively through glutamate synapses on dendritic spines. |
2014-06-02 |
2023-08-13 |
mouse |
| Vanessa A Guzman, Owen T Carmichael, Christopher Schwarz, Giuseppe Tosto, Molly E Zimmerman, Adam M Brickma. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment. Alzheimer's & dementia : the journal of the Alzheimer's Association. vol 9. issue 5 Suppl. 2014-05-28. PMID:23375566. |
current hypothetical models of alzheimer's disease (ad) pathogenesis emphasize the role of β-amyloid (aβ), tau deposition, and neurodegenerative changes in the mesial temporal lobe, particularly the entorhinal cortex and hippocampus. |
2014-05-28 |
2023-08-12 |
Not clear |
| Valeriy Duka, Jae-Hoon Lee, Joel Credle, Jonathan Wills, Adam Oaks, Ciaran Smolinsky, Ketul Shah, Deborah C Mash, Eliezer Masliah, Anita Sidh. Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases. PloS one. vol 8. issue 9. 2014-05-27. PMID:24073234. |
identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and alzheimer's diseases. |
2014-05-27 |
2023-08-12 |
Not clear |
| Valeriy Duka, Jae-Hoon Lee, Joel Credle, Jonathan Wills, Adam Oaks, Ciaran Smolinsky, Ketul Shah, Deborah C Mash, Eliezer Masliah, Anita Sidh. Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases. PloS one. vol 8. issue 9. 2014-05-27. PMID:24073234. |
we examined for the first time epitopes at which tau is hyperphosphorylated in parkinson's disease, dementia with lewy bodies and alzheimer's disease, and also select tau kinases. |
2014-05-27 |
2023-08-12 |
Not clear |
| Di Xia, Jürgen Göt. Premature lethality, hyperactivity, and aberrant phosphorylation in transgenic mice expressing a constitutively active form of Fyn. Frontiers in molecular neuroscience. vol 7. 2014-05-26. PMID:24860422. |
the kinase fyn, the microtubule-associated protein tau and the peptide amyloid-β (aβ) constitute a toxic triad in alzheimer's disease (ad). |
2014-05-26 |
2023-08-13 |
mouse |
| Andréia M Pazini, Guilherme M Gomes, Jardel G Villarinho, Claudio da Cunha, Francielle Pinheiro, Ana P O Ferreira, Carlos F Mello, Juliano Ferreira, Maribel A Rubi. Selegiline reverses aβ₂₅₋₃₅-induced cognitive deficit in male mice. Neurochemical research. vol 38. issue 11. 2014-05-21. PMID:24005822. |
alzheimer's disease (ad) is biochemically characterized by the occurrence of extracellular deposits of amyloid beta peptide (aβ) and intracellular deposits of the hyperphosphorylated tau protein, which are causally related to the pathological hallmarks senile plaques and neurofibrillary tangles. |
2014-05-21 |
2023-08-12 |
mouse |
| Henrik Zetterberg, David Wilson, Ulf Andreasson, Lennart Minthon, Kaj Blennow, Jeffrey Randall, Oskar Hansso. Plasma tau levels in Alzheimer's disease. Alzheimer's research & therapy. vol 5. issue 2. 2014-05-20. PMID:23551972. |
plasma tau levels in alzheimer's disease. |
2014-05-20 |
2023-08-12 |
Not clear |
| Michelle T Fodero-Tavoletti, Shozo Furumoto, Leanne Taylor, Catriona A McLean, Rachel S Mulligan, Ian Birchall, Ryuichi Harada, Colin L Masters, Kazuhiko Yanai, Yukitsuka Kudo, Christopher C Rowe, Nobuyuki Okamura, Victor L Villemagn. Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies. Alzheimer's research & therapy. vol 6. issue 1. 2014-05-20. PMID:24572336. |
assessing thk523 selectivity for tau deposits in alzheimer's disease and non-alzheimer's disease tauopathies. |
2014-05-20 |
2023-08-12 |
Not clear |
| Michelle T Fodero-Tavoletti, Shozo Furumoto, Leanne Taylor, Catriona A McLean, Rachel S Mulligan, Ian Birchall, Ryuichi Harada, Colin L Masters, Kazuhiko Yanai, Yukitsuka Kudo, Christopher C Rowe, Nobuyuki Okamura, Victor L Villemagn. Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies. Alzheimer's research & therapy. vol 6. issue 1. 2014-05-20. PMID:24572336. |
the introduction of tau imaging agents such as (18)f-thk523 offers new hope for the in vivo assessment of tau deposition in tauopathies such as alzheimer's disease (ad), where preliminary (18)f-thk523-pet studies have demonstrated significantly higher cortical retention of (18)f-thk523 in ad compared to age-matched healthy individuals. |
2014-05-20 |
2023-08-12 |
Not clear |
| Claude M Wischik, Charles R Harrington, John M D Store. Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochemical pharmacology. vol 88. issue 4. 2014-05-19. PMID:24361915. |
the alzheimer neurofibrillary tangle is composed of tau and the core of its constituent filaments are made of a truncated fragment from the repeat domain of tau. |
2014-05-19 |
2023-08-12 |
Not clear |
| Miguel Medina, Jesús Avil. New perspectives on the role of tau in Alzheimer's disease. Implications for therapy. Biochemical pharmacology. vol 88. issue 4. 2014-05-19. PMID:24462919. |
new perspectives on the role of tau in alzheimer's disease. |
2014-05-19 |
2023-08-12 |
Not clear |
| M J Hannula, T T Myöhänen, J Tenorio-Laranga, P T Männistö, J A Garcia-Horsma. Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases. Neuroscience. vol 242. 2014-05-16. PMID:23562579. |
prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with parkinson's and alzheimer's diseases. |
2014-05-16 |
2023-08-12 |
human |
| M J Hannula, T T Myöhänen, J Tenorio-Laranga, P T Männistö, J A Garcia-Horsma. Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson's and Alzheimer's diseases. Neuroscience. vol 242. 2014-05-16. PMID:23562579. |
to clarify the possible interaction of prep with other markers of neurodegenerative diseases, we studied colocalizations of prep and (1) α-syn, (2) β-amyloid, (3) tau protein and (4) astroglial and microglial cells in human post-mortem brain samples from pd, alzheimer's disease (ad) patients and in healthy control brain samples. |
2014-05-16 |
2023-08-12 |
human |
| Sachin P Patil, Nhung Tran, Hirosha Geekiyanage, Li Liu, Christina Cha. Curcumin-induced upregulation of the anti-tau cochaperone BAG2 in primary rat cortical neurons. Neuroscience letters. vol 554. 2014-05-16. PMID:24035895. |
alzheimer's disease (ad) is a progressive, neurodegenerative disease characterized by extracellular deposits of amyloid beta (aβ) protein and intracellular neurofibrillary tangles of hyperphosphorylated tau protein. |
2014-05-16 |
2023-08-12 |
human |
| Bess Frost, Martin Hemberg, Jada Lewis, Mel B Fean. Tau promotes neurodegeneration through global chromatin relaxation. Nature neuroscience. vol 17. issue 3. 2014-05-16. PMID:24464041. |
the microtubule-associated protein tau is involved in a number of neurodegenerative disorders, including alzheimer's disease. |
2014-05-16 |
2023-08-12 |
mouse |
| Bess Frost, Martin Hemberg, Jada Lewis, Mel B Fean. Tau promotes neurodegeneration through global chromatin relaxation. Nature neuroscience. vol 17. issue 3. 2014-05-16. PMID:24464041. |
we found widespread loss of heterochromatin in tau transgenic drosophila and mice and in human alzheimer's disease. |
2014-05-16 |
2023-08-12 |
mouse |
| Yongchang Diwu, Jinzhou Tian, Jing Sh. [Effects of Xixin decoction on enzymes related to O-GlcNAc glycosylation of tau proteins in the brain of rats with sporadic Alzheimer's disease]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. vol 33. issue 10. 2014-05-15. PMID:24144743. |
[effects of xixin decoction on enzymes related to o-glcnac glycosylation of tau proteins in the brain of rats with sporadic alzheimer's disease]. |
2014-05-15 |
2023-08-12 |
rat |
| Yongchang Diwu, Jinzhou Tian, Jing Sh. [Effects of Xixin decoction on enzymes related to O-GlcNAc glycosylation of tau proteins in the brain of rats with sporadic Alzheimer's disease]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University. vol 33. issue 10. 2014-05-15. PMID:24144743. |
to study the effects of xixin decoction (xxd) on o-glcnac transferase (ogt) and o-glcnac glycosidase in o-glcnac glycosylation of tau proteins in the brain of rats with sporadic alzheimer's disease (sad) and explore the possible mechanism. |
2014-05-15 |
2023-08-12 |
rat |
| Luis F Maia, Stephan A Kaeser, Julia Reichwald, Michael Hruscha, Peter Martus, Matthias Staufenbiel, Mathias Jucke. Changes in amyloid-β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Science translational medicine. vol 5. issue 194. 2014-05-14. PMID:23863834. |
altered concentrations of amyloid-β (aβ) peptide and tau protein in the cerebrospinal fluid (csf) are thought to be predictive markers for alzheimer's disease (ad). |
2014-05-14 |
2023-08-12 |
mouse |
| Yun Li, Yahong Liu, Zhaojun Wang, Yongjun Jian. Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end? Expert opinion on biological therapy. vol 13. issue 11. 2014-05-12. PMID:24053611. |
amyloid deposit and hyperphosphorylated tau protein contribute to pathological changes seen in alzheimer's disease (ad) and imply that removal may reverse the cognitive decline. |
2014-05-12 |
2023-08-12 |
Not clear |